
Dare Bioscience (NASDAQ:DARE) expects to begin dispensing its prescription sildenafil cream in November, as the women’s health company works to expand sales of its first commercial product and advance two clinical programs toward data readouts in 2027.
On its third-quarter earnings call, President and CEO Sabrina Martucci Johnson said DARE to PLAY Sildenafil Cream was en route to Medvantx, the mail-order pharmacy handling fulfillment. Dispensing is planned initially in the 28 states where the company’s 503B outsourcing facility is licensed.
Sildenafil cream prepares for dispensing
Johnson said 182 office-based providers had written prescriptions for DARE to PLAY before the product became available. Including telehealth providers, prescriptions had been written across 48 states and the District of Columbia.
The cream is being made available by prescription through a registered 503B outsourcing facility while Daré continues discussions with the U.S. Food and Drug Administration about a Phase III program and pursues potential approval through the 505(b)(2) pathway. The company said the facility can advance licensing in additional states once dispensing begins in the 28 states where it is currently licensed.
The product is priced at $99 per tube, which Johnson said provides approximately 10 uses. Patients can seek a prescription through the company’s DARE Health Hub or from their own clinician. Providers can also stock and dispense the cream from their offices; Johnson said the company had received its first such office order.
Daré is working with menopause-focused telehealth provider MyMenopauseRx and is pursuing similar collaborations. Johnson said the company remains open to other partners but wants to protect the product’s pricing and avoid relying too heavily on any one channel.
In response to an analyst’s question, Johnson said compounded sildenafil creams are available but argued that DARE to PLAY is differentiated by its clinical evidence. She also said prescription-level market data for compounded creams are not readily available.
The outsourcing facility, rather than Daré, owns the DARE to PLAY inventory. Johnson said the company expects to book proceeds net of costs associated with the facility and Medvantx. Daré owns the inventory for its nonprescription products.
Flora Sync launch and 2027 pipeline plans
Flora Sync LF5, a non-hormonal probiotic vaginal capsule, is available through the DARE Health Hub and some clinician offices. Johnson said orders had come from 27 states and the company had received its first reorder from a provider’s office. She described first-month revenue as immaterial.
Daré plans to make Flora Sync LF5 available on Amazon in early 2027 and is evaluating other online and brick-and-mortar channels. Two additions to the DARE to RESTORE product family—a vulvar mask and cleanser called Flora Renew and Flora Reset—are also anticipated in early 2027.
The company is targeting 2027 readouts for Ovaprene, an investigational hormone-free monthly contraceptive in a pivotal Phase III study, and DARE-HPV, which is in a Phase II study for persistent high-risk HPV infection. Daré also targets 2027 availability through 503B compounding for DARE to RECLAIM, an estradiol and progesterone vaginal ring.
Johnson said Daré is exploring potential collaborations involving its preclinical DARE-IDDS programmable drug-delivery platform, including applications in obesity, diabetes, hormone therapies and neurologic disease. The technology underlies its grant-supported DARE-LARC1 contraceptive program.
Quarterly results and funding
Chief Accounting Officer MarDee Haring-Layton said Daré ended September with approximately $11.5 million in cash and cash equivalents and $3.2 million in working capital.
Third-quarter revenue rose from approximately $2,000 a year earlier. Selling, general and administrative expenses increased to approximately $2.6 million from $2.5 million, while research and development expense fell to approximately $0.3 million from $1.2 million. The net loss narrowed from approximately $3.6 million in the prior-year quarter.
Haring-Layton cautioned that the low research and development expense reflected the impact of non-dilutive funding and should not be viewed as a measure of the development activity across the portfolio.
Johnson said the company received a $1.5 million installment in October under its DARE-LARC1 grant agreement, bringing total funding received under that agreement to approximately $43.3 million. It also received approximately $852,000 under a Gates Foundation grant supporting Ovaprene and its non-hormonal contraceptive program, bringing total receipts under that agreement to approximately $9.9 million.
About Dare Bioscience (NASDAQ:DARE)
Daré Bioscience is a clinical-stage biopharmaceutical company focused on developing therapies and products for women’s health. Its work spans areas including contraception, vaginal health and sexual health, with an emphasis on addressing conditions and needs that have had limited treatment options. The company’s product candidates include Ovaprene, a hormone-free, monthly-use vaginal contraceptive, and investigational treatments for conditions such as female sexual arousal disorder. These candidates remain in development and are not approved for general use.
